The Effect of a Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers

Sponsor
Uptown Eye Specialists (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05990712
Collaborator
WIlliam Osler Health Systems (Other), Forsee Canada (Other)
68
1
2
4
17

Study Details

Study Description

Brief Summary

This study assesses the impact of two differing ocular hygiene regimens prior to cataract surgery. The first regimen includes an omega-3 supplement and the second without, and both include an at-home lid wipe and cleansing eye drops. These regimens will be assessed on microbial load, inflammation, tear osmolarity, and dry eye metrics. Patients will be randomized to either the omega-3 group + 3-part hygiene regimen, or the group with only the 3-part hygiene regimen. Data will be collected for inflammation through a test (InflammaDry) that measures an inflammatory marker, dry eye metrics via an imaging tool called Oculus 5M and the Canadian Dry Eye Assessment (CDEA) questionnaire, tear osmolarity through Tear Labs device, and area of growth for conjunctiva microbial load by swabbing the conjunctiva of the eye. Dry eye metrics (CDEA and Oculus 5M) will be collected during the patient's baseline appointment, 2-5 days prior to surgery, and post-operative month 1. Microbial load swabs will be collected at baseline, 2-5 days prior to surgery, and date of the surgery. An ocular assessment will also be completed at baseline, one week post-operation, and one month post-operation. All metrics will be compared to the fellow eye. The usage of omega-3 will be compared to the regimen without omega-3.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Omega-3
  • Drug: Trehalose
  • Drug: Zocular Eyelid System Treatment
  • Other: Blephadex cleansing eyelid wipes
Phase 4

Detailed Description

Prospective interventional study assessing the impact of two ocular hygiene regimens, with and without Omega-3, on microbial load, inflammation, tear osmolarity, and dry eye metrics and disease for patients soon to undergo cataract surgery. Study recruitment will occur at Uptown Eye between Sept-Nov 2023, with a target of 68 patients enrolled in the study. Patients will be consecutively randomized to group 1 (without omega 3 group) or group 2 (with omega 3 group). The intervention includes Zocular in clinic at baseline, Thealoz Duo eyedrops twice daily until surgery, and the cleansing wipes twice daily until surgery. The omega 3 group will take the supplement from baseline until one month post-operative.

Data will be collected for inflammation through a InflammaDry Matrix metallopeptidase 9 (MMP-9) test, dry eye through Oculus 5M (measures non-invasive break-up time (NIBUT), lipid layer, bulbar redness, tear meniscus height) and Canadian Dry Eye Assessment (CDEA), TearLab for osmolarity, and conjunctival swabs for microbial load. Dry eye metrics (CDEA and Oculus 5M) will be collected during the patient's baseline Cataract Dry Eye Clinic (CDEC) appointment, 2-5 days prior to surgery, and post-operative month 1. Microbial load will be collected at baseline, 2-5 days prior to surgery, and date of the surgery. Tear osmolarity and inflammation markers will be collected at baseline, 2-5 days prior to surgery, and post-operative month. An ocular assessment will also be completed at baseline, one week post-operation, and post-operative month. All metrics will be compared to the fellow eye.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
68 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients will be assigned to either the omega-3 group or no omega-3 group.Patients will be assigned to either the omega-3 group or no omega-3 group.
Masking:
Single (Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
A Prospective Study on the Effect of Pre-cataract Surgical Ocular Hygiene Regime on Microbial Load, Tear Osmolarity, Dry Eye, and Inflammatory Markers Between Two Ocular Hygiene Regimen Groups
Anticipated Study Start Date :
Sep 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Jan 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Omega-3

Participants in this arm will take oral omega-3 supplement for 4 weeks pre-operatively and 4 weeks post-operatively. They will also receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.

Dietary Supplement: Omega-3
Omega-3 is a fatty acid and there is evidence that the consumption of re-esterified oral omega-3 supplements over the course of 6 to 8 weeks aid in reducing inflammation, dry eye, and optimizing tear osmolarity. The oral omega-3 supplement taken daily.

Drug: Trehalose
Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
Other Names:
  • Thealoz Duo Drops
  • Drug: Zocular Eyelid System Treatment
    A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
    Other Names:
  • ZEST
  • Other: Blephadex cleansing eyelid wipes
    Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.

    Active Comparator: No Omega-3

    Participants in this arm will not take oral omega-3 supplement. They will only receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.

    Drug: Trehalose
    Eyedrops consisting of trehalose and sodium hyaluronate that lubricate and hydrate the eye to relieve dry eye.
    Other Names:
  • Thealoz Duo Drops
  • Drug: Zocular Eyelid System Treatment
    A lid cleaning and debridement system that consists of okra-based gel to relieve dry eye or inflammation. The gel is applied to the eyelid margin and lashes with a cotton swab.
    Other Names:
  • ZEST
  • Other: Blephadex cleansing eyelid wipes
    Eyelid cleansing wipes with tea tree oil and coconut that help reduce infection.

    Outcome Measures

    Primary Outcome Measures

    1. MMP-9 [Baseline, 2-5 days prior to surgery, post-operative month 1]

      Level of MMP-9, an inflammatory marker reported as positive (level of MMP-9 > 40ng/mL) or negative (level of MMP-9 < 40ng/mL).

    2. Microbial load [Baseline, 2-5 days prior to surgery, surgery day]

      Area of microbial growth from conjunctival swab reported as percentage of dish coverage, incubated for 48 hours

    3. Tear osmolarity [Baseline, 2-5 days prior to surgery, surgery day]

      Measure of salt concentration in tear reported as mOsm/L

    Secondary Outcome Measures

    1. Non-invasive break-up time (NIBUT) [Baseline, 2-5 days prior to surgery, post-operative month 1]

      Non-invasive break-up time (NIBUT) is measured using the Oculus 5M and measured in seconds, with longer NIBUT representing better outcomes.

    2. Lipid layer [Baseline, 2-5 days prior to surgery, post-operative month 1]

      Lipid layer is reported in nanometres with higher/thicker lipid layers representing a better outcome.

    3. Bulbar redness [Baseline, 2-5 days prior to surgery, post-operative month 1]

      Bulbar redness is reported by a score from 0-4 with lower scores representing a better outcome.

    4. Tear meniscus height [Baseline, 2-5 days prior to surgery, post-operative month 1]

      Tear meniscus height (TMH) is reported in millimetres, with increases in TMH representing a better outcome.

    5. Canadian Dry Eye Assessment (CDEA) Questionnaire [Baseline, 2-5 days prior to surgery, post-operative month 1]

      12 item questionnaire for reporting of dry eye symptoms on a scale of 0-4. Total scores for the CDEA questionnaire range from 0 to 48 and are interpreted as no dry eye symptoms or normal (<5), mild dry eye symptoms (5-20), moderate dry eye symptoms (21-30), or severe dry eye symptoms (31-48).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients 18 or older who underwent cataract surgical ocular hygiene treatment regimen prior to cataract surgery.

    • Patients of all severity of dry eye will be included.

    Exclusion Criteria:
    • Patients with any other ocular comorbidities (glaucoma, iritis, traumatic eye injury, known systemic autoimmune diseases, immune disorders, anti-inflammatory medications, blood disorders (eg. altered white counts), prior surgery, prior traumatic eye injury, previous dry eye interventions such as ocular plugs, radiofrequency, and IPL).

    • Patients who have any complications arise during the cataract surgery.

    • Patients with altered mental state and cannot provide informed consent.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Uptown Eye Brampton Ontario Canada L6Y 0P6

    Sponsors and Collaborators

    • Uptown Eye Specialists
    • WIlliam Osler Health Systems
    • Forsee Canada

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Uptown Eye Specialists
    ClinicalTrials.gov Identifier:
    NCT05990712
    Other Study ID Numbers:
    • UptownEye4
    First Posted:
    Aug 14, 2023
    Last Update Posted:
    Aug 14, 2023
    Last Verified:
    Aug 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    Yes
    Keywords provided by Uptown Eye Specialists
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 14, 2023